Efficacy and Safety Study in Endometriosis With NBI-56418; Placebo and Active Controlled

Mise à jour : Il y a 4 ans
Référence : NCT00797225

Femme Homme

Extrait

This study is designed to evaluate the safety and beneficial effects of NBI-56418 compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month period followed by an additional three months of treatment on NBI-56418.


Critère d'inclusion

  • Endometriosis


Liens